Stem Flags NYSE Non-Compliance on Market Cap, Adding Delisting Risk

What happened

Stem, Inc. announced on October 19, 2026 that it had notified the NYSE it is not in compliance with Section 802.01B, which requires an average global market capitalization of at least $50 million over a consecutive 30 trading-day period. The company’s stock has fallen sharply from its March 2026 level of $9.70, pushing its market cap below the threshold amid persistent concerns over its weak balance sheet and execution risks. This follows a prior reverse stock split in June 2025 to address sub-$1.00 price non-compliance, indicating repeated exchange listing pressures. STEM now has a limited window to submit a plan to regain compliance, but given its tight liquidity ($48.9M cash, negative working capital, $13.8M debt due within 12 months), the path to recovery is uncertain. The announcement adds a new layer of delisting risk that was not fully reflected in the previous investment thesis.

Implication

Investors should reassess their positions with an emphasis on capital preservation, as the NYSE non-compliance elevates the probability of delisting and forces management to prioritize survival over growth. Even if the underlying software pivot shows improvement, impaired capital markets access may compel the company to raise capital at distressed prices, worsening dilution for existing shareholders. The previous WAIT rating was based on execution of the software-first strategy, but this new development introduces a binary outcome that materially changes the risk/reward. Aggressive traders might attempt to trade volatility, but the prudent stance for most investors is to exit or avoid until a credible compliance plan is approved and the stock stabilizes above key thresholds. Failure to regain compliance could lead to trading on the OTC market, further reducing liquidity and institutional interest.

Thesis delta

The previous WAIT rating was predicated on Stem's ability to execute its software pivot and achieve ARR growth within guidance, but the NYSE non-compliance shifts the thesis from 'prove the turnaround' to 'survive the listing challenge.' The new delisting risk is not fully captured in current valuation and increases the probability of a forced capital raise or distressed outcome. Confidence in the prior thesis is reduced, and we downgrade to AVOID until the company presents a viable plan to restore NYSE compliance and demonstrates sustained progress on liquidity and operations.